Cesca Therapeutics (NASDAQ: KOOL) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.
Institutional and Insider Ownership
3.0% of Cesca Therapeutics shares are held by institutional investors. Comparatively, 6.3% of Kamada shares are held by institutional investors. 3.9% of Cesca Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Cesca Therapeutics has a beta of -0.87, meaning that its stock price is 187% less volatile than the S&P 500. Comparatively, Kamada has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Cesca Therapeutics and Kamada, as provided by MarketBeat.
||Strong Buy Ratings
Kamada has a consensus target price of $8.50, indicating a potential upside of 53.15%. Given Kamada’s stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Cesca Therapeutics.
This table compares Cesca Therapeutics and Kamada’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation and Earnings
This table compares Cesca Therapeutics and Kamada’s revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Kamada has higher revenue and earnings than Cesca Therapeutics. Kamada is trading at a lower price-to-earnings ratio than Cesca Therapeutics, indicating that it is currently the more affordable of the two stocks.
Kamada beats Cesca Therapeutics on 12 of the 14 factors compared between the two stocks.
About Cesca Therapeutics
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.